Adalvo announces the completion of its global dossier for Dolutegravir, a high-value antiretroviral therapy widely recognized for its pivotal role in HIV treatment.
Dolutegravir, a blockbuster anti-HIV product, is a WHO-recommended first-line therapy for HIV, known for its potent viral suppression, low resistance profile, and broad safety across patient populations.
This development reinforces Adalvo’s focus on bringing complex, high-impact treatments to market, with Day-1 launch opportunities in select markets.
Backed by a strong supply chain and global regulatory capabilities, Adalvo is well-positioned to support partners in expanding access to this essential medicine.
With global 2024 sales reaching approximately $1.92 billion, according to IQVIA, Dolutegravir continues to demonstrate strong commercial performance.
Adalvo’s global dossier is now available for registration across multiple markets.
Contact Our Team to Explore Licensing and Commercialization Opportunities for Dolutegravir
Partner up now!